AbbVie (ABBV) announced that it has completed its acquisition of Gilgamesh Pharmaceuticals’ lead investigational candidate, bretisilocin. Bretisilocin is a novel, short-acting serotonin 5-HT2A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback